Precision BioSciences doses first patient in CAR T cell therapy trial
Category: #health  By Nikita Chaurasia  Date: 2019-04-19
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Precision BioSciences doses first patient in CAR T cell therapy trial
  • Precision is creating PBCAR0191 in partnership with Servier, a multinational pharmaceutical firm
     
  • The company believes that the patient dosed in the trial is also the first US-based clinical trial to assess an allogeneic CAR T cell therapy for NHL

The US-based genome editing firm Precision BioSciences has reportedly announced that it has successfully administered the dosage of its very first gene-edited allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate, PBCAR0191, in the Phase 1/2a clinical trial. As per trusted sources, PBCAR0191 is developed from T cells derived from donors which are then altered by utilizing the ARCUS genome editing technology of Precision.

Reportedly, the alterations are designed to create CAR T cells which specifically distinguish CD19 – a significant target in several B-cell cancers – to prevent graft-versus-host ailment. According to a press release by Precision BioSciences, the CAR T cell is being assessed in adult patients with relapsed or refractory non-Hodgkin lymphoma or as an off-the-shelf cell therapy.

The company believes that the patient dosed in the trial is also the first US-based clinical trial to assess an allogeneic CAR T cell therapy for NHL.  This open label, multi-center study of PBCAR0191 is anticipated to register a minimum of 80 patients and numerous dose level of PBCAR0191 would be investigated.

According to a press release by Precision BioSciences, the clinical sites include MD Anderson Cancer Center, Dana-Farber Cancer Institute, and Moffit Cancer Center, and City of Hope. Precision is creating PBCAR0191 in partnership with Servier, a multinational pharmaceutical firm.

For the record, the basic goal of the trial is to assess the safety of PBCAR0191 and decide upon the maximum tolerated dose. The secondary goal is to assess the anti-tumor activity of PBCAR0191.

As per reliable sources, the outcomes of the trail would be collected for up to one year.

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Spotify to allow access to all creators in its video podcast platform

Spotify to allow access to all creators in its video podcast platform

By Nikita Chaurasia

Audio streaming giant Spotify has announced the launch of its video podcast feature, which will be provided by its self-publishing podcast division, Anchor. According to sources, the feature will initially be offered on a rolling basis where interes...

U.K.’s competition regulator might look into the music streaming space

U.K.’s competition regulator might look into the music streaming space

By Nikita Chaurasia

The Competition and Markets Authority of the U.K. has revealed plans to launch a probe targeting the country’s music streaming market to ascertain if it is sufficiently consumer-centric and competitive. The announcement came after a U.K. parli...

India’s vaccination drive slows down as dose gap holds back output

India’s vaccination drive slows down as dose gap holds back output

By Nikita Chaurasia

India’s vaccination efforts have reportedly slowed down despite stockpiling vaccines as authorities are maintaining a more than usual gap between two shots. This is a part of the strategy to boost vaccine coverage in the country. The domestic ...